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ABSTRACT 
Background: Alemtuzumab, an anti-CD52 antibody, is proven to be more efficacious 
than interferon beta-1a in treating relapsing-remitting multiple sclerosis, but its efficacy 
relative to more potent immunotherapies is unknown. 
Methods: We compared effectiveness of alemtuzumab vs. natalizumab, fingolimod 
and interferon β up to five years in propensity-matched patients with relapsing-
remitting multiple sclerosis from MSBase and four other observational cohorts. 
Annualised relapse rates, disability accumulation and disability improvement events 
were compared with clustered weighted models. Secondary analyses examined 
patients with high pre-treatment relapse rate or on-treatment relapses.
Findings: The cohorts consisted of 189 (alemtuzumab), 2155 (interferon), 828 
(fingolimod) and 1160 (natalizumab) patients. Compared to interferon, alemtuzumab 
was associated with lower annualised relapse rate (0·19 vs. 0·53, P<0·001) and similar 
disability outcomes in the overall cohort, and lower risk of disability accumulation 
(hazard ratio=0·64, P=0·018) and a higher rate of disability improvement in patients 
with prior highly active disease (hazard ratio=4, P=0·03). Compared to fingolimod, 
relapse rate was lower on alemtuzumab (0·15 vs. 0·34, P<0·001). Importantly, no 
differences in relapse rate (0·20 vs. 0·19, respectively, P=0·78) and disability 
accumulation rates were found between alemtuzumab and natalizumab. Disability 
improvement rates were lower on alemtuzumab (hazard ratio=0·36, P<0·001) than 
natalizumab, particularly during the first year after commencing therapy. The results 
were largely confirmed by four sensitivity analyses. 
Inerpretation: Alemtuzumab and natalizumab showed similar effects on relapse 
activity and disability accumulation rates in relapsing-remitting multiple sclerosis but 
natalizumab was associated with a greater chance of early disability improvement. 
Alemtuzumab was superior to fingolimod in mitigating relapse activity. 
Funding: This study was financially supported by National Health and Medical 
Research Council and University of Melbourne.  
TEXT 
INTRODUCTION 
Alemtuzumab, an anti-CD52 humanised monoclonal antibody, is a highly effective 
immunotherapy for relapsing-remitting multiple sclerosis (MS).1-3 Through a profound 
pan-lymphocyte depletion and sustained modification of lymphocyte repertoire,4 it 
achieves long-term disease stabilisation in most patients with previously active 
disease.5,6 Pivotal trials have demonstrated its superior effect on relapse activity and 
disability accrual compared with interferon β.2,3
Recent onset of highly active MS, escalation of therapy to natalizumab or alemtuzumab 
following failure of oral medications7 or switch from natalizumab to alemtuzumab or 
fingolimod due to a high risk of progressive multifocal leukoencephalopathy8,9 are 
common scenarios in which alemtuzumab is used in clinical practice. However, there 
is presently no information about the effectiveness of alemtuzumab in comparison to 
the more potent disease modifying therapies. Mixed-treatment analyses of 
alemtuzumab versus other licensed agents were performed during submissions to 
reimbursement agencies (e.g. the National Institute for Health and Care Excellence, 
UK) but public versions of these documents are heavily redacted. This much needed 
evidence is unlikely to emerge from randomised trials as the cost of such long-term 
multi-arm trials is prohibitive.  
Well characterised observational cohorts collect substantial amounts of longitudinal 
information representative of clinical practice. Several cohorts have recently generated 
valuable evidence regarding comparative treatment effectiveness, which is highly 
concordant with clinical trials.10 We have shown that in active MS, highly potent 
therapies, such as natalizumab or fingolimod, are more effective than injectable 
immunotherapies.11,12
The present study compares relapse activity, disability accumulation and disability 
improvement between patients treated with alemtuzumab vs. other immunotherapies. 
First, we aimed to replicate the results of the pivotal trials of alemtuzumab vs. interferon 
β. Then, we explored the effectiveness of alemtuzumab in comparison with 
natalizumab or fingolimod over up to five years of treatment. 
METHODS 
The MSBase cohort study (registered with WHO ICTRP, ID ACTRN12605000455662) 
was approved by the Melbourne Health Human Research Ethics Committee, and by 
the site institutional review boards (or exemptions were granted, according to local 
regulations). Written informed consent was obtained from enrolled patients, as 
required. 
Patients and follow-up 
Longitudinal clinical data from 96 MSBase centres in 30 countries and patients treated 
with alemtuzumab from six MS centres in Cambridge,5 Cardiff, Bristol, Swansea,6
Dublin and Dresden13 were extracted between November 2015 and June 2016 and 
evaluated for inclusion criteria. These consisted of the following: definite relapsing-
remitting MS,14,15 exposure to one of the study therapies, no prior exposure to 
hematopoietic stem cell transplantation, no participation in randomised clinical trials, 
minimum required recorded follow-up (12 months prior to treatment start and two on-
treatment disability scores ≥6 months apart) and minimum dataset (consisting of sex, 
age, time of first MS symptom, dates of clinical relapses, clinical MS course, disability 
score at treatment commencement (-6 months to +3 months), ≥6-month persistence 
on study therapy, ≥1 relapse experienced within the year before treatment, age ≤65 
years, time from first MS symptom ≤10 years and Expanded Disability Status Scale 
(EDSS) score ≤6·5.  
Treatment protocols, which involved alemtuzumab (12-24mg i.v. daily for five days 
(cycle 1) or three days (cycle 2)), interferon β-1a (44μg s.c. thrice weekly), fingolimod 
(0·5mg oral daily) and natalizumab (300μg i.v. every four weeks) were described 
elsewhere.5,6,11 Baseline was defined as the first commencement of the study therapy 
and patients were censored at discontinuing therapy, commencing the first post-
baseline disease modifying therapy or at the last recorded EDSS, whichever occurred 
first. 
The analysed data were recorded as part of quality clinical practice, mostly at tertiary 
MS centres, with data entry at the time of clinical visits. The MSBase protocol stipulates 
minimum annual updates of the minimum dataset, but patients with less frequent visits 
were not excluded. Data entry portals included iMed, MSBase online data entry 
system, PatientCare, MSDS or local data entry systems. Rigorous quality assurance 
procedure was applied (Table S2).16
Study endpoints 
The primary endpoint was the on-treatment annualised relapse rate. Secondary 
endpoints consisted of the cumulative hazard of relapses, disability accumulation 
events and disability improvement events. 
A relapse was defined as occurrence of new symptoms or exacerbation of existing 
symptoms persisting for ≥24 hours, in the absence of concurrent illness/fever, and 
occurring ≥30 days after a previous relapse. Confirmation of relapses by EDSS was 
not required. Individual annualised relapse rate between baseline and censoring was 
calculated. 
Disability was scored by accredited EDSS scorers (Neurostatus certification was 
required at the participating centres), excluding any score recorded within 30 days of 
a previous relapse. The definitions of disability accumulation and improvement 
required confirmation over ≥6 months, as described elsewhere.17
Matching and statistical analysis 
Matching and statistical analysis were conducted using R (version 3·0·3)18, in three 
separate paired matched analyses of alemtuzumab vs. interferon β, fingolimod or 
natalizumab. Individual patients were matched on their propensity of receiving either 
of the compared therapies.12,19 Individual propensity scores were calculated using a 
multivariable logistic improvement model of treatment allocation that utilised 
demographic and clinical variables available at the time of treatment assignation as 
independent variables: sex, age, time from first MS symptom, EDSS, number of 
relapses in the prior 12 months, number of prior MS therapies, and the perceived most 
effective prior MS therapy. 
Patients were matched in a variable 2:1 ratio using nearest neighbour matching within 
a narrow caliper (0·1 standard deviations of the propensity score), without 
replacement. All subsequent analyses were designed as paired models with weighting 
to adjust for the variable matching ratio. A maximum cumulative weight for each 
matched patient was 1. The common on-treatment follow-up was determined in each 
matched pair as the shorter of the two patient follow-up periods (pairwise censoring), 
in order to control attrition bias.10
Tests of statistical inference were carried out at α=0·05 with familywise Benjamini-
Hochberg correction for false discovery rate. After assessing normality of data 
distribution, annualised relapse rates were compared with a weighted negative 
binomial model with cluster effect for matched patient pairs and adjusted for visit 
frequency. Relapse rates at years 1-5 were compared with weighted paired t-tests. 
Cumulative hazards of relapses, EDSS accumulation and improvement events were 
analysed with weighted conditional proportional hazards models with robust estimation 
of variance (Andersen-Gill) adjusted for visit frequency. The proportions of patients 
free from relapse, EDSS accumulation and with EDSS improvement were evaluated 
with weighted conditional proportional hazards models (Cox) adjusted for visit 
frequency. Where the proportionality of hazards assumption was violated (assessed 
with Schoenfeld’s global test), interaction term for treatment and time was included in 
the multivariable models.  
Robustness of the statistically significant differences to unidentified confounders was 
quantified with Hodges-Lehmann Γ.20 Where no statistically significant differences 
were observed, analytical power was quantified as the minimum effect magnitude 
detectable within the available cohort at 1-β=0·8 using simulations (n=200). 
Secondary and sensitivity analyses 
Two secondary analyses and four sensitivity analyses were completed. The secondary 
analyses compared the therapies (i) among patients with high pre-baseline relapse 
activity (defined as ≥2 relapses within 12 months or ≥3 relapses within 24 months pre-
baseline, irrespective of treatment status) and (ii) any prior on-treatment break-through 
relapses. The former used a 10:1 variable matching ratio in order to maximise 
analytical power. The sensitivity analyses evaluated the robustness of the results to 
potential confounders, including matching (using 10:1 variable matching within a 
caliper of 0·4), pre-baseline follow-up (matching on the number of relapses in the prior 
24 months), MS phenotype (allowing inclusion of patients with secondary progressive 
MS), follow-up duration (including patients with ≥2-year on-treatment follow-up) and 
confirmation of EDSS accumulation/improvement events over ≥12 months. 
Role of the funding source 
The study (including study design, the collection, analysis, and interpretation of data, 
writing of the report, and in the decision to submit the paper for publication) was 
conducted separately and apart from the guidance of the sponsors. 
RESULTS 
A total of 189, 2155, 828 and 1160 patients fulfilling the inclusion criteria and treated 
with alemtuzumab (from 1999), interferon β (from 1994), fingolimod (from 2010) and 
natalizumab (from 2006) were identified, respectively (Figure 1, Table S3). One 
hundred and five (55%) patients treated with alemtuzumab received two treatment 
cycles and 84 patients (45%) required additional treatment cycles. As expected, the 
four unmatched groups differed in their baseline characteristics (Table S4). As shown 
by the logistic regression models used to calculate propensity scores, patients 
commenced alemtuzumab earlier after their first MS presentation, at a younger age, 
and tended to have higher EDSS scores and pre-baseline relapse activity compared 
to the three other therapies (Table S5).  
The numbers of patients retained in the matched cohorts for all three pairwise primary 
analyses are shown in Table 1. The matching procedure significantly decreased the 
between-group differences in propensity scores from 0·24-0·44 to 0·0001-0·0026, 
corresponding to a >99·4% improvement in the balance between the compared 
groups. This is reflected by their close match on individual characteristics with 
standardised differences of ≤15% (Table 1). The median differences between baseline 
date and the date of the baseline EDSS were comparable between the matched 
cohorts (-14-0 days [quartiles -71 to +12], standardised difference 0.02-0.19). As a 
result of pairwise censoring, on-treatment follow-up was identical in the matched 
groups. The groups were not matched on the follow-up visit density, therefore all 
subsequent analyses were adjusted for visit frequency. 
Patients treated with alemtuzumab experienced a lower annualised relapse rate 
compared with interferon β (mean [95% confidence intervals] 0·19 [0·14-0·23] vs. 0·53 
[0·46-0·61], respectively, P<0·001; Figure 2). While a consistent decline in the relapse 
rate was observed in the interferon β group over the five years on treatment 
(representing time-dependent decline in relapse activity21), the difference between the 
groups remained significant throughout the follow-up. Cumulative hazard of relapse 
events was lower in the alemtuzumab group (hazard ratio 0·60, P=0·005). The primary 
analysis did not show any differences in the cumulative hazards of disability 
accumulation or improvement (P≥0·66). However, the secondary analyses (in addition 
to confirming the differences in relapse outcomes) showed that alemtuzumab was 
associated with a lower hazard of disability accumulation than interferon β in patients 
with high pre-baseline relapse activity and higher probability of disability improvement 
in patients with previous on-treatment break-through relapses (Table S6). 
Similarly, patients treated with alemtuzumab showed lower annualised relapse rate 
compared with fingolimod (mean [95% confidence intervals] 0·15 [0·10-0·20] vs. 0·34 
[0·26-0·41], P<0·001; Figure 3). This observation was consistent during years 1-3, for 
which sufficient cohorts were available. The difference in cumulative hazard of 
relapses failed to reach the level of statistical significance (P=0·18). No between-group 
differences in the cumulative hazards of disability accumulation or improvement were 
observed. 
The comparison between alemtuzumab and natalizumab showed similar on-treatment 
annualised relapse rates over four years (mean [95% confidence intervals] 0·20 [0·14-
0·26] vs. 0·19 [0·15-0·23], P=0·78; Figure 4), confirmed by equivalence in the 
cumulative hazard of relapses (P=0·83) and probability of remaining relapse free 
(P=0·65). Cumulative hazard of disability accumulation events was also similar 
(P=0·60). However, alemtuzumab was associated with lower cumulative probability of 
disability improvement than natalizumab (hazard ratio 0·35, P<0·001). This difference 
in disability outcomes was also confirmed among patients with high pre-baseline 
relapse activity. 
Sensitivity analyses have confirmed the outcomes of the primary and secondary 
analyses (with the exception of disability outcomes in the comparison of alemtuzumab 
vs. interferon β). The comparisons of the rates of disability accumulation and 
improvement events confirmed over 6-months were also largely replicated in the 
sensitivity analysis requiring a 12-month confirmation interval. Modifying the matching 
ratio and caliper, pre-baseline observational period, inclusion of secondary progressive 
MS and minimum on-treatment follow-up did not significantly change the overall 
relapse and disability outcomes (see Table S6). 
Where the primary analysis did not show any significant differences between the 
compared groups, analysis of the minimum detectable effect size was carried out 
(Table S7). The analyses were sufficiently powered to detect minimum differences of 
0·13 relapse per year, 51-53% cumulative hazard of relapses, 35-66% cumulative 
hazard of disability accumulation and 39-42% cumulative probability of disability 
improvement. The differences in annualised relapse rates observed for alemtuzumab 
vs. interferon β and fingolimod were resistant to unknown confounders with relative 
magnitudes of >100% and 60% of the reported effect of treatment (Hodges-Lehmann 
Γ), respectively.
DISCUSSION 
In this large combined observational propensity score-matched study of patients with 
relapsing-remitting multiple sclerosis, alemtuzumab and natalizumab were equally 
effective in reducing relapse frequency and preventing confirmed disability 
accumulation over four years. However, natalizumab was more likely to lead to 
disability improvement, particularly during the first year after commencing therapy. 
Compared to fingolimod, alemtuzumab was superior in reducing relapse activity. No 
differences were found between alemtuzumab and fingolimod in their ability to 
modulate the risk of disability accumulation or improvement events over three years.  
In order to enable interpretation of these results in the context of the original pivotal 
clinical trials, we have first conducted a comparison of alemtuzumab vs. high-dose 
interferon β-1a. This study has partially replicated the results of these pivotal trials: 
alemtuzumab is superior to interferon β in suppressing relapse activity and reducing 
disability accrual in patients with previously highly active MS. The observed on-
treatment annualised relapse rates (0·19 vs. 0·53, alemtuzumab vs. interferon β, 
respectively) are comparable to the relapse rates reported by the CAMMS223 (0·16 
vs. 0·54), CARE-MS1 (0·18 vs. 0·39) and CARE-MS2 (0·26 vs. 0·52) trials. The 
proportion of patients who experienced 6-month confirmed accumulation of disability 
at two years was similar between the present study (7% vs. 12%, alemtuzumab vs. 
interferon β, respectively) and the CARE-MS1 trial (8% vs. 11%), with neither being 
significantly different. However there was a treatment effect on disability accumulation 
events in the CAMMS223 (6% vs. 16%) and CARE-MS2 (13% vs. 20%) trials at two 
years. It should be noted that the cohorts are not directly comparable; the 
alemtuzumab trials recruited patients with ≥2 relapses during the preceding two years, 
while inclusion into our primary analysis was based on ≥1 relapse during the preceding 
one year. Our secondary analyses, which only included patients with high pre-baseline 
activity (≥2 relapses during the one year or ≥3 relapses during the two years pre-
baseline) and previous break-through on-treatment relapses showed improved 
disability outcomes in alemtuzumab compared with interferon β (decreased cumulative 
hazard of disability accumulation and increased probability of disability improvement, 
respectively). Thus, our results from patients with highly active MS are concordant with 
those produced in the relevant comparative alemtuzumab versus interferon β trials.
The on-treatment annualised relapse rates observed in the natalizumab and fingolimod 
groups (0·19 and 0·34, respectively) are in keeping with the previously reported on-
treatment MS activity form MSBase11,12 and the pivotal trials for natalizumab (0·20-
0·24)22 and are higher than the annualised relapse rates reported in the pivotal trials 
for fingolimod (0·16-0·20)23,24. In keeping with our previous observation of superior 
control of disease activity after escalating therapy to natalizumab compared with 
fingolimod, alemtuzumab was comparable to natalizumab but superior to fingolimod in 
preventing MS relapses. Both effects were sustained over at least 3-4 years following 
the commencement of therapy. While the hazard of disability accumulation was similar 
for alemtuzumab and both natalizumab and fingolimod, treatment with natalizumab 
increased the probability of confirmed disability improvement more than alemtuzumab. 
This extends prior observations that natalizumab, unlike fingolimod, is likely to increase 
the probability of partial recovery from the previously accumulated neurological 
disability, in particular during the initial years after first MS presentation.12,25
In the present study, we maximised analytical power by combining several high-quality 
longitudinal observational MS cohorts.5,6 Cumulative follow-up and generalisability 
were maximised by inclusion of a broad spectrum of patients with the minimum follow-
up requirements necessary to evaluate confirmed disability outcomes. Both, treatment-
naïve patients and patients previously exposed to immunotherapies were included.  
Because the assembled study cohort is, by definition, multicentric, we have undertaken 
multiple steps to mitigate the potential biases, including matching, pairwise censoring 
and adjusting the statistical models,10 an approach whose efficacy was demonstrated 
in our previous studies.11,12 The alemtuzumab cohorts were enriched for patients with 
early, highly active disease. Given the large number of patients treated with 
natalizumab, fingolimod or interferon β available from the MSBase cohort, we were 
able to achieve close match on their demographic and clinical characteristics. Because 
the probability of capturing treatment discontinuation was relatively lower in the 
alemtuzumab cohort, we have mitigated the risk of differential follow-up duration by 
pairwise censoring. It is arguable that our approach was underpowered to detect some 
clinically significant treatment effects.  
The main limitation, in comparison to controlled studies, is the lack of systematic and 
comparable acquisition of safety data and of radiological outcomes. Magnetic 
resonance imaging is an important indicator of subclinical disease activity, with 
potential impact on disease management. If unreported and systematically different 
between the compared cohorts, it could represent an unidentified confounder. Another 
potential confounder is the effect of treating centre. Due to the limited overlap between 
the centres reporting patients treated with alemtuzumab and the three comparator 
therapies, we were not able to match on or adjust for centre, but we have mitigated the 
effect by adjusting the analyses for visit frequency, which served as an indicator of 
follow-up density. Importantly, we have shown that our results were robust to 
hypothetical unidentified confounders of the magnitude >60% of the difference in 
treatment effects. The definition of MS relapses used in our study did not require 
confirmation by change in EDSS, which reflects usual clinical practice; this was 
different from several clinical trials which required EDSS confirmation. This study 
compared treatment outcomes in observational data over 3-5 years. It is worth noting 
that disability accumulation events confirmed over 6-12 months are highly indicative of 
long-term disability outcomes.17 Comparative evaluation of the long-term safety of 
alemtuzumab and natalizumab is warranted, as treatment safety represents an 
important component of disease management strategy. 
In conclusion, we show that - over three to five years - alemtuzumab is a highly 
effective disease modifying therapy in relapsing-remitting MS, with a treatment effect 
largely comparable to natalizumab, and with greater effect on relapse rate than 
fingolimod or interferon β-1a.  
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RESEARCH IN CONTEXT 
Evidence before this study 
Alemtuzumab, is a highly effective therapy for multiple sclerosis. Similar to 
natalizumab, another highly effective multiple sclerosis therapy, it has shown an 
effective control of multiple sclerosis activity and reduction in disability accrual. In a 
number of scenarios, clinicians and their patients are faced with the decision 
between alemtuzumab or natalizumab (such as early active treatment in aggressive 
multiple sclerosis, escalation of therapy following failure of other therapies or switch 
from natalizumab to alemtuzumab due to a high risk of natalizumab-associated 
serious adverse events). No evidence comparing the efficacy of alemtuzumab and 
natalizumab is available to guide these clinical decisions.  
Added value of this study 
This study provides a conclusive evidence comparing effectiveness of alemtuzumab 
vs. natalizumab and fingolimod (another novel immunotherapy) for multiple sclerosis. 
Alemtuzumab and natalizumab show similar effects on relapse activity and disability 
accumulation but natalizumab is associated with a greater chance of early disability 
reduction. Alemtuzumab is superior to fingolimod in mitigating relapse activity. 
Implications of all the available evidence 
While alemtuzumab is superior in controlling multiple sclerosis activity relative to 
fingolimod, its efficacy is largely comparable to that of natalizumab. Therefore, 
treatment decisions between alemtuzumab and natalizumab should be primarily 
governed by the therapies’ safety profiles.
FIGURE LEGENDS 
Figure 1 
CONSORT diagram of patient disposition 
EDSS, Expanded Disability Status Scale; MS, multiple sclerosis 
Figure 2 
Comparison of the treatment outcomes for alemtuzumab vs. interferon β
Figure 3 
Comparison of the treatment outcomes for alemtuzumab vs. fingolimod 
Figure 4 
Comparison of the treatment outcomes for alemtuzumab vs. natalizumab 
Table 1 
Characteristics of the matched patient groups at baseline 
alemtuzumab interferon β d alemtuzumab fingolimod d alemtuzumab natalizumab d
patients, nr (% female) 124 (73%) 218 (74%) 114 (72%) 195 (73%) 138 (70%) 223 (66%)
age, yr, mean ± SD 33 ± 8 33 ± 9 0·01 33 ± 8 34 ± 10 0·09 33 ± 9 33 ± 10 0·02
disease duration, yr, 
median (quartiles)
3·2 
(2-6·2)
2·6 
(1·2-6·4)
0·01 3·9 
(2·4-6·6)
4·2 
(1·6-8·1)
0·13 3·3 
(2·1-6·3)
2·7 
(1-7·6)
0·13
relapses 12 months pre-
baseline, mean ± SD
2 ± 1·2 1·9 ± 0·9 0·06 1·8 ± 1·1 1·7 ± 0·8 0·03 2 ± 1·3 2 ± 1 0·03
disability, EDSS step, 
median (quartiles)
3 
(2-4)
3 
(2-4)
0·12 3 
(1·6-4)
3 
(1·5-4·5)
0·00 3 
(2-4·5)
3 
(2-4·5)
0·01
inter-visit interval, months, 
median (quartiles)
9 
(7-13)
4 
(2-7)
0·72 9 
(6-12)
3 
(2-5)
1·17 9 
(6-12)
3 
(1-5)
1·12
previous therapies, nr, 
median (quartiles)
0 
(0-1)
0 
(0-1)
0·01 1 
(0-1)
1 
(0-2)
0·11 0 
(0-1)
0 
(0-1)
0·15
most active previous therapy, patients
Interferon β/Glatiramer 
acetate
31 (25%) 62 (28%) 46 (40%) 85 (44%) 47 (34%) 97 (43%)
Teriflunomide 0 0 0 0 0 0
Dimethyl fumarate 0 0 0 0 0 0
Fingolimod 0 0 0 0 2 (1%) 4 (2%)
Natalizumab 3 (2%) 4 (2%) 14 (12%) 22 (11%) 0 0
Mitoxantrone 3 (2%) 4 (2%) 2 (2%) 5 (3%) 0 0
other 0 0 0 0 0 0
none 87 (70%) 148 (68%) 52 (46%) 83 (43%) 89 (64%) 122 (55%)
post-baseline pairwise-
censored follow-up on 
study therapy, yr, median 
(quartiles)
2·1 
(1·0-3·9)
2·1 
(1·0-3·9)
0·00 1·7 
(1·1-2·3)
1·7 
(1·1-2·3)
0·00 2·1 
(1·4-3·4)
2·1 
(1·4-3·4)
0·00
d, standardised difference (Cohen’s d); SD, standard deviation; EDSS, Expanded Disability Status Scale 
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Table S1 
List of contributors
The following contributors participated in data acquisition: 
From Hospital Universitario Virgen de Valme, Spain, Dr Ricardo Fernandez Bolaños. 
From Ospedali Riuniti di Salerno, Italy, Dr Gerardo Iuliano. 
From Péterfy Sandor Hospital, Hungary, Dr Krisztina Kovacs. 
From Veszprém Megyei Csolnoky Ferenc Kórház zrt., Hungary, Dr Imre Piroska. 
From CIREN, Havana, Cuba, Dr Jose Antonio Cabrera-Gomez. 
From MS Clinic, Hopital Tenon, Paris, France, Dr Etienne Roullet. 
From University Hospital Nijmegen, Nijmegen, Netherlands, Dr Cees Zwanikken. 
From Francicus Ziekenhuis, Roosendaal, Netherlands, Dr Leontien Den braber-Moerland. 
From Hospital Fernandez, Capital Federal, Argentina, Dr Norma Deri. 
From INEBA - Institute of Neuroscience Buenos Aires, Buenos Aires, Argentina, Dr Maria Laura 
Saladino. 
From Instituto de Neurociencias Cordoba, Cordoba, Argentina, Dr Elizabeth Alejandra Bacile. 
From Sanatorio Allende, Cordoba, Argentina, Dr Carlos Vrech. 
From Geelong Hospital, Geelong, Australia, Dr Cameron Shaw. 
From St Vincents Hospital, Fitzroy, Melbourne, Australia, Dr Neil Shuey. 
From Monash Medical Centre, Melbourne, Australia, Dr Ernest Butler. 
From The Alfred, Melbourne, Australia, Dr Olga Skibina. 
From Austin Health, Melbourne, Australia, Dr Richard Macdonell. 
From Royal Brisbane and Women's Hospital, Brisbane, Australia, Dr Pamela McCombe. 
From CSSS Saint-Jérôme, Saint-Jerome, Canada, Dr Julie Prevost. 
From Jewish General Hospital, Montreal, Canada, Dr Fraser Moore. 
From Hospital Clinico San Carlos, Madrid, Spain, Dr Celia Oreja-Guevara. 
From Craigavon Area Hospital, Craigavon, United Kingdom, Dr Stella Hughes. 
From Royal Victoria Hospital, Belfast, United Kingdom, Dr Gavin McDonnell. 
From South East Trust, Belfast, United Kingdom, Dr Orla Gray. 
From Josa András Hospital, Nyiregyhaza, Hungary, Dr Tunde Erdelyi. 
From Petz A. County Hospital, Gyor, Hungary, Dr Gabor Rum. 
From BAZ County Hospital, Miskolc, Hungary, Dr Attila Sas. 
From Szent Imre Hospital, Budapest, Hungary, Dr Eniko Dobos. 
From Assaf Harofeh Medical Center, Beer-Yaakov, Israel, Dr Shlomo Flechter. 
From Bombay Hospital Institute of Medical Sciences, Mumbai, India, Dr Bhim Singhal. 
From Isfahan University of Medical Sciences, Isfahan, Iran, Dr Vahid Shaygannejad. 
From University of Florence, Florence, Italy, Dr Maria Pia Amato. 
From Clinic of Neurology Clinical Center, Skopje, Macedonia, Dr Tatjana Petkovska-Boskova. 
From Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands, Dr Erik van Munster. 
From Hospital São João, Porto, Portugal, Dr Maria Edite Rio. 
From Central Military Emergency University Hospital, Bucharest, Romania, Dr Carmen Sirbu. 
From New York University Langone Medical Center, New York, United States, Dr Ilya Kister. 
From G. d’Annunzio University, Chieti, Italy, Dr Giovanna De Luca, Dr Valeria Di Tommaso, Dr Daniela 
Travaglini, Dr Erika Pietrolongo, Dr Maria di Ioia, Dr Deborah Farina, Dr Luca Mancinelli. 
From Box Hill Hospital, Melbourne, Australia, Ms Jodi Haartsen. 
From Azienda Sanitaria Unica Regionale Marche - AV3, Macerata, Italy, Dr Matteo Diamanti, Dr 
Elisabetta Cartechini. 
From Nuovo Ospedale Civile Sant'Agostino/Estense, Modena, Italy, Dr Diana Ferraro, Dr Francesca 
Vitetta, Dr Anna Maria Simone. 
From Jahn Ferenc Teaching Hospital, Budapest, Hungary, Dr Krisztian Kasa. 
From Hospital Italiano, Buenos Aires, Argentina, Dr Juan Ingacio Rojas. 
Administrative and technical support was provided by:  
From the MSBase Administrations Dr Jill Byron, Ms Lisa Morgan and Ms Eloise Hinson.  
From Rodanotech, Geneva, Switzerland; Mr Samir Mechati, Mr Matthieu Corageoud, Mr Alexandre 
Bulla. 
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Table S2 
Data quality procedure  
• Duplicate patient records were removed. • Centres with <10 patient records were excluded. • Patients with missing date of birth were excluded. • MS onset dates after the MSBase data extract date were removed. • Patients with missing date of the first clinical presentation of MS were excluded. • The dates of MS onset and the first recorded MS course were aligned. • Patients with the age at onset outside the 0-100 range were excluded. • A logical sequence of the MS courses (e.g. clinically isolated syndrome, relapsing-
remitting MS, secondary progressive MS) was assured. • Records of the initiation of the progressive MS prior to its clinical onset were excluded. • Visits with missing visit date or the recorded date before the clinical MS onset or after 
the date of MSBase data extract were removed. • EDSS scores outside the range of possible EDSS values were removed. • Duplicate visits were merged. • MS relapses with missing visit date or the recorded date after the date of MSBase data 
extract were removed. • Duplicate MS relapses were merged. • Relapses occurring within 30 days of each other were merged. • Visits preceded by relapses were identified and time from the last relapse was 
fcalculated for each visit. • Therapies were labelled as discontinued or continuing. • Therapies with erroneous date entries were removed (e.g. commencement date > 
termination date, commencement after the MSBase data extract date, commencement 
of disease modifying therapy before the year 1980). • MS disease modifying therapies were identified and labelled. • Duplicate treatment entries were removed. • Where multiple disease modifying therapies were recorded simultaneously, treatment 
end date of the previous therapy was imputed as the commencement date of the 
following therapy. • Consecutive entries for certain disease modifying therapies were merged into a 
continuous treatment entry, given that the gap between the entries did not exceed 190 
days for mitoxantrone, 365 days for cladribine, 90 days for other disease modifying 
therapies. • The default duration of treatment effect was recorded as 190 days (mitoxantrone), 5 
years (alemtuzumab) or 365 days (cladribine) from treatment commencement.
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Table S3 
Patient disposition per centre 
Centre Patients
Hospital Fernandez, Capital Federal, Argentina 3
INEBA - Institute of Neuroscience Buenos Aires, Buenos Aires, Argentina 5
Instituto de Neurociencias Cordoba, Cordoba, Argentina 1
Hospital Italiano, Buenos Aires, Argentina 14
Sanatorio Allende, Cordoba, Argentina 3
Brain and Mind Centre, Sydney, Australia 10
University of Melbourne, Melbourne, Australia 117
University Newcastle, Newcastle, Australia 74
Geelong Hospital, Geelong, Australia 8
St Vincents Hospital, Fitzroy, Melbourne, Australia 3
Monash Medical Centre, Melbourne, Australia 1
Liverpool Hospital, Sydney, Australia 18
Box Hill Hospital, Melbourne, Australia 100
Westmead Hospital, Sydney, Australia 23
Flinders University, Adelaide, Australia 47
Royal Brisbane and Women's Hospital, Brisbane, Australia 22
The Alfred, Melbourne, Australia 5
Austin Health, Melbourne, Australia 5
Royal Brisbane and Women's Hospital, Brisbane, Australia 2
Cliniques Universitaires Saint-Luc, Brussels, Belgium 60
CSSS Saint-Jérôme, Saint-Jerome, Canada 7
Jewish General Hospital, Montreal, Canada 5
Hopital Notre Dame, Montreal, Canada 166
CISSS Chaudière-Appalache, Levis, Canada 147
Neuro Rive-Sud, Quebec, Canada 53
General University Hospital and Charles University in Prague, Prague, Czech Republic 721
Nemocnice Jihlava, Jihlava, Czech Republic 16
Kommunehospitalet, Arhus C, Denmark 38
Hospital Universitario Virgen de Valme, Seville, Spain 64
Hospital Universitario Donostia, San Sebastián, Spain 34
Hospital Clinico San Carlos, Madrid, Spain 29
Hospital Universitario Virgen Macarena, Sevilla, Spain 300
Hospital de Galdakao-Usansolo, Galdakao, Spain 17
Hospital Germans Trias i Pujol, Badalona, Spain 15
MS Clinic, Hopital Tenon , Paris, France 2
Craigavon Area Hospital, Craigavon, United Kingdom 5
Royal Victoria Hospital, Belfast, United Kingdom 5
South East Trust, Belfast, United Kingdom 3
University of Cambridge, Cambridge, United Kingdom 84
University Hospital of Wales, Cardiff; Southmead Hospital, Bristol; Abertawe Bro 
Morgannwg University Local Health Board, Swansea, United Kingdom 82
University Hospital Carl Gustav Carus, Dresden, Germany 9
Veszprém Megyei Csolnoky Ferenc Kórház zrt., Veszprem, Hungary 14
Jahn Ferenc Teaching Hospital, Budapest, Hungary 59
Semmelweis University Budapest, Budapest, Hungary 16
University of Debrecen, Debrecen, Hungary 16
Péterfy Sandor Hospital, Budapest, Hungary 18
Josa András Hospital, Nyiregyhaza, Hungary 7
Petz A. County Hospital , Gyor, Hungary 6
BAZ County Hospital, Miskolc, Hungary 8
Szent Imre Hospital, Budapest, Hungary 9
Assaf Harofeh Medical Center, Beer-Yaakov, Israel 14
Bombay Hospital Institute of Medical Sciences, Mumbai, India 3
St Vincent's University Hospital, Dublin, Ireland 8
Isfahan University of Medical Sciences, Isfahan, Iran 4
Ospedale Clinicizzato, Chieti, Italy 173
Azienda Sanitaria Unica Regionale Marche - AV3, Macerata, Italy 83
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University of Bari, Bari, Italy 560
University of Florence, Florence, Italy 14
C. Mondino National Neurological Institute, Pavia, Italy 32
Ospedali Riuniti di Salerno, Salerno, Italy 29
University of Parma, Parma, Italy 49
Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino, Avellino, Italy 47
Nuovo Ospedale Civile Sant'Agostino/Estense, Modena, Italy 79
Amiri Hospital, Kuwait City, Kuwait 94
Clinic of Neurology Clinical Center, Skopje, Macedonia 4
University Hospital Nijmegen, Nijmegen, Netherlands 29
Francicus Ziekenhuis, Roosendaal, Netherlands 4
Zuyderland Ziekenhuis, Sittard, Netherlands 79
Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands 1
Groene Hart Ziekenhuis, Gouda, Netherlands 25
Hospital São João, Porto, Portugal 11
Central Military Emergency University Hospital, Bucharest, Romania 1
KTU Medical Faculty Farabi Hospital, Trabzon, Turkey 50
19 Mayis University, Samsun, Turkey 64
New York University Langone Medical Center, New York, United States 3
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Table S4 
Characteristics of the included unmatched patients at baseline
alemtuzumab interferon β fingolimod natalizumab
patients, nr (% female) 189 (69%) 2155 (72%) 828 (73%) 1160 (71%)
age, yr, mean ± SD 33 ± 8 34 ± 9 38 ± 10 36 ± 9
disease duration, yr, 
median (quartiles) 
3.2  
(1.8-5.9) 
3.6  
(1.3-7.9) 
7.8  
(3.8-14.1) 
7.4  
(3.3-12.4) 
relapses 12 months pre-
baseline, mean ± SD 
2.3 ± 1.4 1.5 ± 0.7 1.4 ± 0.7 1.7 ± 0.9 
disability, EDSS step, 
median (quartiles) 
3.5  
(2-5.5) 
2  
(1.5-3) 
2.5  
(1.5-4) 
3  
(2-4) 
visit interval, months, 
median (quartiles) 
9 
(6-12) 
3 
(1-5) 
4 
(3-5) 
3 
(1-5) 
treatment cycles, patients 
1 12 (6%) - - -
2 93 (49%) - - -
3 60 (31%) - - -
4 15 (8%) - - -
5 9 (5%) - - -
previous therapies, nr, 
median (quartiles) 
0 
(0-1) 
0 
(0-1) 
1 
(1-2) 
1 
(1-2) 
most active previous therapy, patients
Interferon β / Glatiramer 
Acetate 
49 (26%) 523 (24%) 566 (68%) 956 (82%) 
Teriflunomide 0 0 2 (0.002%) 5 (0.004%)
Dimethyl fumarate 0 0 4 (0.005%) 2 (0.002%)
Fingolimod 2 (1%) 3 (0.001%) 0 51 (4%)
Natalizumab 15 (8%) 4 (0.002%) 112 (14%) 0
Mitoxantrone 3 (2%) 18 (1%) 20 (2%) 0
other 2 (1%) 4 (0.002%) 1 (0.001%) 0
none 118 (62%) 1606 (75%) 123 (15%) 146 (13%)
post-baseline follow-up on 
study therapy, yr, median 
(quartiles) 
5.4  
(3.5-7.5) 
2.8  
(1.5-5.1) 
1.9  
(1.3-2.7) 
2.2  
(1.6-3.6) 
SD, standard deviation; EDSS, Expanded Disability Status Scale 
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Table S5 
Logistic regression models used to estimate the propensity scores 
Alemtuzumab (reference) vs. Interferon β
Coefficient  Std.Error      z  Pr(>z)     
(Intercept)                  4.83479    0.41071  11.772  < 2e-16 *** 
sex [male]                  -0.10662    0.19113  -0.558 0.576955     
age                          0.01367    0.01016   1.346 0.178415     
disease duration             0.07927    0.02336   3.393 0.000692 *** 
baseline disability, EDSS   -0.61612    0.05615 -10.974  < 2e-16 *** 
relapses, previous 1 year   -0.66905    0.08348  -8.014 1.11e-15 *** 
previous treatment starts   -0.68819    0.21652  -3.178 0.001481 **  
the most active previous therapy 
 [azathioprine]            -17.17696  571.95611  -0.030 0.976042     
 [cladribine]               11.20600  882.74346   0.013 0.989872     
 [fingolimod]               -2.05513    1.11778  -1.839 0.065978 .   
 [interferon/glat.acetate]   0.59337    0.34280   1.731 0.083463 .   
 [mitoxantrone]              0.91399    0.80023   1.142 0.253388     
 [natalizumab]              -2.90462    0.83616  -3.474 0.000513 *** 
Alemtuzumab (reference) vs. Fingolimod 
Coefficient  Std.Error      z  Pr(>z)
(Intercept)                  0.78359    0.47883   1.636 0.101741     
sex [male]                   0.14652    0.23931   0.612 0.540369     
age                          0.05385    0.01332   4.043 5.28e-05 *** 
disease duration             0.09866    0.02669   3.697 0.000218 *** 
baseline disability, EDSS   -0.62584    0.07279  -8.598  < 2e-16 *** 
relapses, previous 1 year   -0.75061    0.11190  -6.708 1.97e-11 *** 
previous treatment starts    0.50871    0.18517   2.747 0.006011 **  
the most active previous therapy 
 [azathioprine]            -17.84382 1569.65081  -0.011 0.990930     
 [cladribine]               13.22411 2399.54476   0.006 0.995603     
 [fingolimod]              -19.28791 1661.61895  -0.012 0.990738     
 [interferon/glat.acetate]   1.53649    0.34143   4.500 6.79e-06 *** 
 [mitoxantrone]              0.07270    0.90885   0.080 0.936245     
 [natalizumab]               0.54180    0.58717   0.923 0.356151     
 [dimethyl fumarate]        15.78815 1130.34093   0.014 0.988856     
 [teriflunomide]            15.24303 1577.02981   0.010 0.992288 
Alemtuzumab (reference) vs. Natalizumab 
Coefficient  Std.Error      z  Pr(>z)
(Intercept)                  0.75124    0.45410   1.654 0.098059 .   
sex [male]                   0.34616    0.21922   1.579 0.114319     
age                          0.02076    0.01122   1.851 0.064215 .   
disease duration             0.06619    0.02457   2.693 0.007071 **  
baseline disability, EDSS   -0.28078    0.06028  -4.658 3.19e-06 *** 
relapses, previous 1 year   -0.33535    0.08911  -3.763 0.000168 *** 
previous treatment starts    0.36423    0.21001   1.734 0.082855 .   
the most active previous therapy  
 [azathioprine]            -17.84255 1668.79190  -0.011 0.991469     
 [fingolimod]                1.97703    0.84384   2.343 0.019135 *   
 [interferon/glat.acetate]   2.00707    0.36181   5.547 2.90e-08 *** 
 [mitoxantrone]            -17.40004 1343.03379  -0.013 0.989663     
 [natalizumab]             -17.88766  591.72883  -0.030 0.975884     
 [dimethyl fumarate]        15.61481 1686.86823   0.009 0.992614     
 [teriflunomide]            15.16167 1053.31694   0.014 0.988515 
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Table S6  
Results of the secondary and sensitivity analyses 
The table shows observed annualised relapse rate or hazard ratios (HR) for the evaluated outcomes, together with the corresponding p values. Of the two compared disease 
modifying therapies (DMT), interferon β served as a reference. The p values (adjusted for false discovery rate) ≤0.05 are highlighted in red.
alemtuzumab vs. interferon β-1a annualised relapse rate cumulative hazard of 
relapses
cumulative hazard of 
the first relapse
analysis alemtuzumab interferon β alemtuzumab interferon β
primary analysis 189 2155 156 282 0.19 vs 0.53, p=3.5e-16 HR=0.6, p=0.0052 HR=0.59, p=0.072
secondary analyses
high pre-baseline activity (>=3 relapses over 24 months or 
>=2 relapses over 12 months pre-baseline), 1:10 match
150 1053 118 696 0.19 vs 0.58, p=9.8e-80 HR=0.38, p=1.5e-09 HR=0.27, p<0.001
an on-DMT relapse recorded pre-baseline 28 491 17 148 0.36 vs 0.58, p=0.011 HR=0.61, p=0.3 HR=0.34, p=2.6e-06
sensitivity analyses
1:10 match with broad caliper (0.4) 189 2155 159 1049 0.18 vs 0.51, p=2.4e-16 HR=0.4, p=5.2e-14 HR=0.25, p<0.001
matching on 24-month pre-baseline relapse activity 189 2155 150 270 0.14 vs 0.52, p=1.6e-41 HR=0.31, p=3.9e-12 HR=0.23, p<0.001
relapsing and secondary progressive MS 191 2201 159 290 0.16 vs 0.52, p=1.5e-38 HR=0.35, p=1.1e-08 HR=0.26, p<0.001
minimum of 2-year on-treatment follow-up 168 1391 124 218 0.16 vs 0.38, p=3e-17 HR=0.46, p=7.3e-06 HR=0.35, p=2.7e-11
n, unmatched n, matched
alemtuzumab vs. interferon β-1a
analysis
confirmed at 6 
months
confirmed at 12 
months
confirmed at 6 
months
confirmed at 12 
months
confirmed at 6 months
confirmed at 12 
months
confirmed at 6 
months
confirmed at 12 
months
primary analysis HR=0.66, p=0.37 HR=0.59, p=0.31 HR=0.69, p=0.42 HR=0.63, p=0.33 HR=0.98, p=0.93 HR=0.84, p=0.65 HR=1.4, p=0.4 HR=1.1, p=0.76
secondary analyses
high pre-baseline activity (>=3 relapses over 24 months or 
>=2 relapses over 12 months pre-baseline), 1:10 match
HR=0.64, p=0.018HR=0.65, p=0.029HR=0.92, p=0.71 HR=0.74, p=0.096 HR=0.98, p=0.94 HR=0.68, p=0.41 HR=2.1, p=0.00047 HR=1.9, p=0.0033
an on-DMT relapse recorded pre-baseline HR=1.1, p=0.93 HR=1.1, p=0.93 HR=0.83, p=0.86 HR=0.83, p=0.86 HR=3.9, p=0.035 HR=3.9, p=0.03 HR=4.2, p=0.0037 HR=4.2, p=0.0037
sensitivity analyses
1:10 match with broad caliper (0.4) HR=0.82, p=0.21 HR=0.79, p=0.15 HR=1, p=0.93 HR=0.77, p=0.065 HR=0.99, p=0.96 HR=0.51, p=0.013 HR=1.3, p=0.14 HR=1.2, p=0.46
matching on 24-month pre-baseline relapse activity HR=0.97, p=0.89 HR=0.91, p=0.74 HR=1.4, p=0.28 HR=1.1, p=0.73 HR=1, p=0.92 HR=1.1, p=0.9 HR=1.2, p=0.72 HR=1.2, p=0.74
relapsing and secondary progressive MS HR=0.9, p=0.69 HR=0.82, p=0.56 HR=1.3, p=0.46 HR=0.99, p=1 HR=1.1, p=0.71 HR=1.1, p=0.87 HR=1.4, p=0.33 HR=1.4, p=0.35
minimum of 2-year on-treatment follow-up HR=0.9, p=0.77 HR=0.87, p=0.79 HR=0.89, p=0.78 HR=0.88, p=0.79 HR=0.89, p=0.75 HR=0.76, p=0.52 HR=1.1, p=0.84 HR=0.96, p=0.9
cumulative hazard of the first disability 
improvement event
cumulative hazard of disability 
accumulation events
cumulative hazard of the first 
disability accumulation event
cumulative hazard of disability improvement 
events
Kalincik et al., Supplementary Appendix 
Page 9 of 11
The table shows observed annualised relapse rate or hazard ratios (HR) for the evaluated outcomes, together with the corresponding p values. Of the two compared disease 
modifying therapies (DMT), fingolimod served as a reference. The p values (adjusted for false discovery rate) ≤0.05 are highlighted in red.
alemtuzumab vs. fingolimod annualised relapse rate
cumulative hazard of 
relapses
cumulative hazard of 
the first relapse
analysis alemtuzumab fingolimod alemtuzumab fingolimod
primary analysis 189 828 114 195 0.15 vs 0.34, p=1.4e-11 HR=0.62, p=0.18 HR=0.59, p=0.065
secondary analyses
high pre-baseline activity (>=3 relapses over 24 months or 
>=2 relapses over 12 months pre-baseline), 1:10 match
150 372 82 261 0.16 vs 0.32, p=7e-07 HR=0.63, p=0.24 HR=0.62, p=0.039
an on-DMT relapse recorded pre-baseline 28 646 22 173 0.23 vs 0.28, p=0.92 HR=0.83, p=0.94 HR=0.78, p=0.66
sensitivity analyses
1:10 match with broad caliper (0.4) 189 828 116 532 0.15 vs 0.3, p=1.3e-14 HR=0.7, p=0.27 HR=0.51, p=4.6e-06
matching on 24-month pre-baseline relapse activity 189 828 95 167 0.15 vs 0.34, p=0.00039 HR=0.49, p=0.0054 HR=0.39, p=0.00023
relapsing and secondary progressive MS 191 862 115 192 0.15 vs 0.31, p=0.0016 HR=0.68, p=0.3 HR=0.67, p=0.21
minimum of 2-year on-treatment follow-up 168 388 77 107 0.13 vs 0.27, p=0.00025 HR=0.67, p=0.36 HR=0.74, p=0.49
n, unmatched n, matched
alemtuzumab vs. fingolimod
analysis
confirmed at 6 
months
confirmed at 12 
months
confirmed at 6 
months
confirmed at 12 
months
confirmed at 6 months
confirmed at 12 
months
confirmed at 6 
months
confirmed at 12 
months
primary analysis HR=1.3, p=0.67 HR=0.38, p=0.29 HR=1.7, p=0.39 HR=1.2, p=0.85 HR=0.5, p=0.18 HR=0.48, p=0.19 HR=0.5, p=0.17 HR=0.61, p=0.36
secondary analyses
high pre-baseline activity (>=3 relapses over 24 months or 
>=2 relapses over 12 months pre-baseline), 1:10 match
HR=0.93, p=0.94 HR=0.78, p=0.7 HR=1.1, p=0.81 HR=0.82, p=0.76 HR=0.6, p=0.4 HR=0.66, p=0.57 HR=0.73, p=0.54 HR=0.63, p=0.38
an on-DMT relapse recorded pre-baseline HR=0.94, p=1 HR=1.7, p=0.7 HR=1, p=0.97 HR=1.5, p=0.9 HR=1.1, p=1 HR=0.75, p=0.94 HR=0.96, p=0.98 HR=1, p=1
sensitivity analyses
1:10 match with broad caliper (0.4) HR=0.89, p=0.94 HR=1.1, p=0.95 HR=0.95, p=0.93 HR=0.82, p=0.61 HR=0.54, p=0.12 HR=0.59, p=0.26 HR=0.6, p=0.095 HR=0.62, p=0.12
matching on 24-month pre-baseline relapse activity HR=1.4, p=0.73 HR=1.3, p=0.73 HR=1.7, p=0.44 HR=1.3, p=0.74 HR=0.64, p=0.53 HR=0.61, p=0.51 HR=0.72, p=0.7 HR=0.77, p=0.71
relapsing and secondary progressive MS HR=0.71, p=0.63 HR=0.62, p=0.58 HR=1, p=1 HR=0.71, p=0.66 HR=0.69, p=0.5 HR=0.71, p=0.63 HR=0.77, p=0.65 HR=1, p=1
minimum of 2-year on-treatment follow-up HR=1.7, p=0.53 HR=1.7, p=0.55 HR=1.3, p=0.81 HR=1.5, p=0.82 HR=0.41, p=0.088 HR=0.41, p=0.097 HR=0.4, p=0.096 HR=0.45, p=0.17
cumulative hazard of disability 
accumulation events
cumulative hazard of the first 
disability accumulation event
cumulative hazard of disability improvement 
events
cumulative hazard of the first disability 
improvement event
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The table shows observed annualised relapse rate or hazard ratios (HR) for the evaluated outcomes, together with the corresponding p values. Of the two compared disease 
modifying therapies (DMT), natalizumab served as a reference. The p values (adjusted for false discovery rate) ≤0.05 are highlighted in red.
alemtuzumab vs. natalizumab annualised relapse rate
cumulative hazard of 
relapses
cumulative hazard of 
the first relapse
analysis alemtuzumab natalizumab alemtuzumab natalizumab
primary analysis 187 1160 138 223 0.2 vs 0.19, p=0.78 HR=1, p=0.83 HR=0.87, p=0.65
secondary analyses
high pre-baseline activity (>=3 relapses over 24 months or 
>=2 relapses over 12 months pre-baseline), 1:10 match
148 711 103 382 0.17 vs 0.2, p=0.25 HR=0.97, p=0.92 HR=0.97, p=0.93
an on-DMT relapse recorded pre-baseline 28 953 19 188 0.28 vs 0.3, p=0.16 HR=0.83, p=0.97 HR=0.5, p=0.012
sensitivity analyses
1:10 match with broad caliper (0.4) 187 1160 139 662 0.18 vs 0.19, p=0.49 HR=1, p=0.93 HR=0.78, p=0.093
matching on 24-month pre-baseline relapse activity 187 1160 111 181 0.21 vs 0.23, p=0.73 HR=1.1, p=0.93 HR=0.9, p=0.73
relapsing and secondary progressive MS 189 1198 141 226 0.19 vs 0.2, p=0.65 HR=1, p=1 HR=0.74, p=0.3
minimum of 2-year on-treatment follow-up 166 684 106 160 0.18 vs 0.17, p=0.86 HR=1.2, p=0.76 HR=0.83, p=0.68
n, unmatched n, matched
alemtuzumab vs. natalizumab
analysis
confirmed at 6 
months
confirmed at 12 
months
confirmed at 6 
months
confirmed at 12 
months
confirmed at 6 months
confirmed at 12 
months
confirmed at 6 
months
confirmed at 12 
months
primary analysis HR=0.81, p=0.6 HR=0.92, p=0.84 HR=1.1, p=0.84 HR=0.71, p=0.53 HR=0.35, p=0.00058 HR=0.46, p=0.061 HR=0.73, p=0.57 HR=0.59, p=0.34
secondary analyses
high pre-baseline activity (>=3 relapses over 24 months or 
>=2 relapses over 12 months pre-baseline), 1:10 match
HR=0.83, p=0.68 HR=0.88, p=0.79 HR=0.98, p=0.95 HR=0.5, p=0.047 HR=0.44, p=0.0023 HR=0.54, p=0.069 HR=0.74, p=0.38 HR=0.79, p=0.52
an on-DMT relapse recorded pre-baseline HR=1.2, p=0.82 HR=1.3, p=0.82 HR=1, p=1 HR=1, p=0.98 HR=1.2, p=0.88 HR=1.7, p=0.31 HR=1.2, p=0.92 HR=1.3, p=0.92
sensitivity analyses
1:10 match with broad caliper (0.4) HR=0.81, p=0.58 HR=0.92, p=0.92 HR=1, p=0.95 HR=0.64, p=0.092 HR=0.35, p=0.00032 HR=0.46, p=0.038 HR=0.54, p=0.0012 HR=0.56, p=0.0049
matching on 24-month pre-baseline relapse activity HR=0.77, p=0.75 HR=0.92, p=0.91 HR=0.62, p=0.41 HR=0.6, p=0.45 HR=0.43, p=0.01 HR=0.4, p=0.01 HR=0.62, p=0.3 HR=0.54, p=0.17
relapsing and secondary progressive MS HR=0.81, p=0.65 HR=0.86, p=0.7 HR=0.79, p=0.64 HR=0.52, p=0.22 HR=0.34, p=2e-04 HR=0.47, p=0.069 HR=0.59, p=0.2 HR=0.59, p=0.23
minimum of 2-year on-treatment follow-up HR=0.79, p=0.79 HR=0.84, p=0.73 HR=0.35, p=0.017 HR=0.33, p=0.015 HR=0.69, p=0.35 HR=0.56, p=0.21 HR=0.91, p=0.83 HR=0.86, p=0.72
cumulative hazard of the first disability 
improvement event
cumulative hazard of disability 
accumulation events
cumulative hazard of the first 
disability accumulation event
cumulative hazard of disability improvement 
events
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Table S7 
Results of the power analyses 
annualised 
relapse rate
cumulative 
hazard of 
relapses
cumulative hazard 
of disability 
progression
cumulative 
probability of 
disability 
regression
interferon β - - 40% 42%
fingolimod - 53% 66% 39%
natalizumab 0.13 51% 35% -
The table shows minimum detectable differences for alemtuzumab vs. interferon β, fingolimod or 
natalizumab, for the disease outcomes whose analyses did not reach the predefined level of statistical 
significance. The differences are shown as relapses per year (for annualised relapse rate) or proportion 
of the cumulative hazard (for the cumulative hazard of relapses, disability progression or disability 
regression). 
